APAC Healthcare Weekly (Oct 11) – Shionogi, Terumo, Ono Pharma, Celltrion, Hanmi Pharm, CSL
Shionogi is acquiring IntraBio for $2B. Ono stuck inlicensing deal with Biohaven. Hanmi’s obesity drug got approval in Korea. CSL terminates supply...
86 Views
APAC Healthcare Weekly (Oct 4) – Hengrui, Hansoh, Chugai Pharma, Daiichi Sankyo, Otsuka, Sun Pharma
Hengrui stuck $2.6B outlicensing deal with Novo. EC revoked EU marketing authorization of Hansoh’s aumolertinib. Otsuka initiates NDA submission to...
97 Views
China Healthcare Weekly Wrap (28 Sep - 2 Oct)
Strong deal flows this week: 1) Abogen/Novartis on in vivo mRNA TCE; 2) Scibrunch/Merck on Kras G12D, 3) Hengrui/Novo on weekly oral GLP-1/GIP;...
94 Views
Primer: Daiichi Sankyo (4568 JT) - Aug 2026
Daiichi Sankyo is successfully transitioning into a global oncology powerhouse, driven by its industry-leading Antibody-Drug Conjugate (ADC)...
91 Views
Primer: Daiichi Sankyo (4568 JP) - Aug 2026
Daiichi Sankyo is successfully transitioning into a global oncology leader, driven by its innovative and proprietary DXd antibody-drug...
104 Views